Liver involvement in Gaucher disease - Review and clinical approach

Blood Cells Mol Dis. 2018 Feb:68:66-73. doi: 10.1016/j.bcmd.2016.10.001. Epub 2016 Oct 19.

Abstract

Gaucher disease (GD), one of the most prevalent lysosomal storage diseases, is associated with glucocerebroside accumulation in cells of the monocyte-macrophage system in various organs, including the liver. Evaluating and managing liver disease in patients with Gaucher disease may be challenging. While hepatic involvement is common in Gaucher disease, its severity, and clinical significance span a wide spectrum, ranging from sub-clinical involvement to liver cirrhosis with its associated complications including portal hypertension. Apart from liver involvement in Gaucher disease, patients with may also suffer from other comorbidities involving the liver. That Gaucher disease itself can mimic hepatic lesions, affect laboratory tests used to characterize liver disease, and may be associated with non-cirrhotic portal hypertension, complicates the diagnostic approach even more. Better understanding of liver involvement in Gaucher disease can spare patients unnecessary invasive testing, and assist physicians in decision making when evaluating patients with Gaucher disease suspected for significant liver disease. This review describes the various clinical manifestations, laboratory and imaging abnormalities that may be encountered when following patients with Gaucher disease for liver involvement. The mechanism for liver disease are discussed, as well as the possible hepato-protective effect of glucocerebroside, and the a diagnostic and treatment approaches.

Keywords: Gaucher disease; Liver disease.

Publication types

  • Review

MeSH terms

  • Animals
  • Gaucher Disease / blood
  • Gaucher Disease / complications*
  • Gaucher Disease / pathology*
  • Gaucher Disease / therapy
  • Glucosylceramides / blood
  • Humans
  • Liver / pathology*
  • Liver Diseases / blood
  • Liver Diseases / complications*
  • Liver Diseases / pathology*
  • Liver Diseases / therapy

Substances

  • Glucosylceramides